Építés alatt – nem éles oldal
Belépés
Visszavonva2. fázis

HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis

A legfontosabb adatok

Ki végzi
Hope Biosciences Research Foundation
Hol
Sugar Land (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Fázis
2. fázis
Kezdés
2026. jan.
Befejezés
2026. jan.
A vizsgálat típusa
Beavatkozással járó, 3 csoport
A vizsgált kezelések
  • allogeneic Hope Biosciences adipose-derived mesenchymal stem cells
  • Normal Saline Solution 0.9%
A regiszteradat frissítve
2026. január 7.
Miért állt le
In the time that the site has been active, there have been 0 patients enrolled despite our best efforts. It is clear that it is not feasible to conduct this study at this time; therefore, we have withdrawn this study.

Ki vehet részt

Életkor
2 év – 16 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 25 feltétel megnézéseKevesebb

Ki vehet részt

  • The subject will be eligible for inclusion in this clinical trial only if all of the following criteria apply:
  • Male and female subjects who are ≥ 2 years old and < 17 years old; a.The first 6 subjects enrolled must be ≥ 12 years old and < 17 years old
  • Must be diagnosed with Oligoarticular or Polyarticular Juvenile Idiopathic Arthritis by a Pediatric Rheumatologist
  • Must have rheumatoid factor (RF) factor test result documented in medical records
  • Must have at least 3 affected joints at the screening visit
  • Must have a body weight of > 10 kg at the screening visit
  • Subjects without a current established treatment for JIA who are not on treatment because they have failed at least 2 approved medications for their condition, or if being treated, subjects who are on a stable dose of arthritis therapy regimen for ≥3 months prior to screening
  • Must have an abnormal CRP result and/or abnormal ESR result at screening. Abnormal C-reactive protein (CRP) value defined as > 1 mg/dL. Abnormal Erythrocyte Sedimentation Rate (ESR) value defined as >15 mm/hr for males and >20 mm/hr for females
  • Female study subjects of childbearing potential should not be pregnant or plan to become pregnant during study participation and for 6 months after the last investigational product administration. Female study subjects of childbearing potential must confirm usage of one of the following contraceptive measures:; Hormonal contraceptives associated with ovulation inhibition (oral, injectable, implantable, patch, or intravaginal); Intrauterine device (IUD), or intrauterine hormone-releasing system (IUS); Barrier contraceptive methods (condoms, diaphragm, etc.)
  • Male subjects if their sexual partners can become pregnant should ensure the use one of the following methods of contraception during study participation and for 6 months after the last administration of the investigated product; Hormonal contraceptives associated with ovulation inhibition (oral, injectable, implantable, patch, or intravaginal); Intrauterine device (IUD), or intrauterine hormone-releasing system (IUS); Barrier contraceptive methods (condoms, diaphragm, etc.)
  • Study subject's parent(s)/LAR is/are able and willing to comply with the requirements of this clinical trial
  • Voluntarily signed informed consent from study subjects' parent(s) or legally authorized representative obtained before any clinical-trial related procedures are performed

Ki nem vehet részt

  • Study subject has 1 or more significant uncontrolled concurrent medical conditions (verified by medical records), including the following:; Diabetes Mellitus; Crohn's Disease; Lupus; Multiple Sclerosis
  • Study subject has received any stem cell treatment within 1 year before first dose of investigational product other than stem cells produced by Hope Biosciences LLC
  • Receiving any investigational therapy or any approved therapy for investigational use within 1 year prior first dose of the investigational product other than COVID-19 vaccines
  • Study subject with known concurrent acute or chronic viral hepatis B or C or human immunodeficiency virus (HIV) infection
  • Study subject with any systemic infection requiring treatment with antibiotics, antivirals, or antifungals within 30 days prior to first dose of the investigational product
  • Study subject has any active malignancy, including evidence of cutaneous basal, squamous cell carcinoma or melanoma
  • Study subject has any of the following laboratory results at the screening visit:; WBC: <3000 cells/μL OR >15000 cells/μL (<3 K cells/μL or >15 K cells/μL); Hemoglobin: <8 g/dL; Absolute Neutrophil Count: <1500 cells/μL; Platelet: <150000 cells/μL (<150 K cells/μL); Sodium: <120 mEq/L OR >150 mEq/L; Glucose: >150 mg/dL; Potassium: <3.5 mEq/L OR >6 mEq/L; BUN: >25 mg/dL; Creatinine: >2 mg/dL; BUN/Creatinine ratio: >50; AST: >100 U/L; ALT: >100 U/L
  • Study subject has any other laboratory abnormality or medical condition which, in the opinion of the investigator, poses a safety risk or will prevent the subject from completing the study
  • The subject will not be eligible for inclusion in this clinical trial if any of the following criteria apply:
  • Study participant has any vital sign abnormalities at the screening visit as determined by the investigator
  • Study subject has known alcoholic addiction or dependency or has current substance use or abuse
  • Study subject's parent(s)/LAR unable to understand and provide signed informed consent
  • Study subject and/or study subject's parent(s)/LAR unlikely to complete the study or adhere to the study procedures

Helyszínek itt: Egyesült Államok

  • Hope Biosciences Research FoundationSugar Land, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Methodology: Randomized, double-blind, AB/BA cross-over study with a washout period of 12 weeks.

A teljes eredeti leírásKevesebb

Treatment Duration: 8 weeks per group

General Objectives: To assess the efficacy and safety of multiple intravenous infusions of allogeneic HB-adMSCs by improving signs and symptoms of juvenile idiopathic arthritis in this subject population.

Number of Subjects: 66 (6 subjects in Cohort 1 and 60 subjects in Cohort 2)

Indication: Juvenile Idiopathic Arthritis

A vizsgálat 3 csoportja

  • Cohort 2: Group ABA vizsgált kezelés

    Cohort 2 - Group AB will receive allogeneic HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) at study weeks 0, 4, and 8. Then, Group AB will receive placebo (Sterile Saline Solution 0.9%) at weeks 20, 24, and 28 after a washout period of 12 weeks between active treatment and placebo.

    Kezelés: allogeneic Hope Biosciences adipose-derived mesenchymal stem cells és Normal Saline Solution 0.9%

  • Cohort 2: Group BAA vizsgált kezelés

    Cohort 2 - Group BA will receive placebo (Sterile Saline Solution 0.9%) at study weeks 0, 4, and 8. Then, Group BA will receive allogeneic HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) at weeks 20, 24, and 28 after a washout period of 12 weeks between placebo and active treatment.

    Kezelés: allogeneic Hope Biosciences adipose-derived mesenchymal stem cells és Normal Saline Solution 0.9%

  • Cohort 1: Group AA vizsgált kezelés

    Cohort 1 - Group A will receive allogeneic HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) at study weeks 0, 4, and 8.

    Kezelés: allogeneic Hope Biosciences adipose-derived mesenchymal stem cells

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Double-Blind, Phase 2, Efficacy and Safety Cross-Over Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis
A regiszteradat frissítve
2026. január 7.